Article detail · 2025 · article
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial
Journal
The Lancet Oncology
OpenAlex
SJR Q1
JCR Q1
Top 10%
Year2025
Citations12OpenAlex
Percentile%98.0
FWCI8.141.00 = world average
Scopus (SJR)Q1
WoS (JCR)Q1
Data source split
- YÖKSİS venueThe Lancet Oncology
- OpenAlexOpenAlex enrichment (abstract, citations, topics)
Abstract
Abstract not compiled yet; it will appear after the DergiPark / OpenAlex queue runs.
Topics
Citations
OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.
12citationsOpenAlex · cited_by_count (cache / database)
Authors
No author information.